Adam Laponis Sells 2,399 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 2,399 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer directly owned 110,276 shares of the company’s stock, valued at approximately $10,402,335.08. This represents a 2.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adam Laponis also recently made the following trade(s):

• On Friday, April 17th, Adam Laponis sold 4,000 shares of Twist Bioscience stock. The stock was sold at an average price of $60.00, for a total transaction of $240,000.00.
• On Tuesday, April 14th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The stock was sold at an average price of $55.00, for a total transaction of $165,000.00.

Twist Bioscience Stock Up 2.4%

Shares of NASDAQ:TWST opened at $92.53 on Wednesday. The firm has a market capitalization of $5.76 billion, a PE ratio of -69.57 and a beta of 2.11. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $105.47. The firm has a fifty day moving average of $75.69 and a 200 day moving average of $56.93.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm had revenue of $110.72 million for the quarter, compared to the consensus estimate of $107.64 million. During the same quarter last year, the company posted ($0.66) earnings per share. Twist Bioscience’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, research analysts anticipate that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TWST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Robert W. Baird upped their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. UBS Group set a $89.00 price objective on Twist Bioscience in a research note on Monday, June 15th. Barclays lifted their price objective on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. Finally, Piper Sandler assumed coverage on Twist Bioscience in a research note on Thursday, June 11th. They issued an “overweight” rating and a $85.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $87.30.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors have recently added to or reduced their stakes in TWST. Western Wealth Management LLC purchased a new position in shares of Twist Bioscience in the first quarter valued at about $31,000. Strs Ohio purchased a new stake in shares of Twist Bioscience during the first quarter worth about $33,000. GAMMA Investing LLC grew its stake in shares of Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after purchasing an additional 185 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after purchasing an additional 453 shares during the period. Finally, Quarry LP bought a new position in Twist Bioscience during the 3rd quarter valued at approximately $28,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.